Risk Factors in Young Middle Eastern Women With Cardiovascular Disease

Overview

Cardiovascular disease continues to be the leading cause of death among women in the Middle East, including Jordan. Sex-specific data focused on cardiovascular disease have been increasing steadily, yet is not the subgroup of young women. This study focuses on classical and novel risk factors of cardiovascular disease in young women compared with older women.

Full Title of Study: “Classical Risk Factors in Young Middle Eastern Women With Atherosclerotic Cardiovascular Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 31, 2022

Detailed Description

This is the introduction of a new study at Istishari entitled: "The Classical Risk Factors in Young Middle Eastern Women with Atherosclerotic Cardiovascular Disease" This is an investigator-initiated, cross-sectional, non-interventional, observational study. Medical research in Jordan is a basic responsibility of all medical sectors in the country. Despite the drastic growth and advances of medical services, the volume of the local medical research is, at best estimate, scarce. The emerging role of private medical groups, private hospitals, and residency programs in cooperation with other medical sectors and medical schools, in conducting, presenting, and publishing such studies should be encouraged and supported. A major indicator of judging the credibility and quality of any medical research project is to look at the conferences the research was presented at and the journals it was published in. This is the 10th major project of the Jordan Collaborating Cardiology Group (JCC) and the first in cooperation with the Istishari Hospital Internal Medicine Residency Program (see Appendix 1. Timeline of JCC Group studies) The first project was JoHARTS that evaluated coronary risk factors and dyslipidemia in 5000 individuals with ACS, stable CAD, and non CAD patients. The 2nd project was CAPRIS evaluated the prognostic implications of hs-CRP in ACS from admission to 1 year. The 3rd project was MINTOR that evaluated onset, triggers, reperfusion strategies, and hospital mortality in more than 950 Jordanians with acute ST-elevation MI. The 4th project was GLORY study that evaluated the prevalence of glucometabolic states among ACS patients, prognosis up to 1 year, and TIMI risk score . The 5th was JoPCR1 that evaluated outcome post PCI in 2426 ACS and non ACS patients in 12 tertiary care centers for the incidence of death, stent thrombosis, revascularization, bleeding, impact of gender, DM, renal dysfunction, and age on outcome, GRACE, and CRUSADE risk scores. The 6th is the colchicine study of AF prevention in open heart surgery, one is completed with 1 mg dose and one is ongoing with reduced dose. The 7th and 8th projects are ongoing and study statin eligibility in patients admitted with MI (Statin EPIC) and decade or more survivors after coronary revascularization. The 8th was the Jordanian AF study which evaluated patients with AF in ambulatory and out-patient settings. The 9th was the JoCORE study that evaluated acute CV events due to the stresses of the covid-19 pandemic. One population subgroup is under studied in the world literature as well as the local literature. The young women who have documented CVD. This group represents only a small proportion of the CVD population in all countries.

Interventions

  • Other: Observing cardiovascular risk factors
    • Documenting the presence or absence of CVD risk factors in each participant.

Arms, Groups and Cohorts

  • Young Women
    • Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
  • Older Women
    • Older women, aged >50 years, with documented atherosclerotic cardiovascular disease

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of classical CVD risk factors
    • Time Frame: August 2021 to September 2020.
    • To study the prevalence of the 4 classical risk factors (HTN, DM, smoking, and dyslipidemia) in young women (younger than 50 years of age) who have documented CVD in ambulatory and in-patient settings and compare the data with women older than 50 y of age with CVD.

Secondary Measures

  • Prevalence of novel/emerging CVD risk factors
    • Time Frame: August 2021 to September 2022.
    • To study emerging non traditional risk factors, and demographic baseline features of these patients including family history, BMI, PCOS, hormone medications, sport activities.. etc.

Participating in This Clinical Trial

Inclusion Criteria

  • Women aged 18 y or more. – Documented CVD (CAD stable or ACS, PCI, CABG, CVA/TIA, carotid disease, PAD). Exclusion Criteria:

  • Women younger than 18 years of age. – No documented CVD.

Gender Eligibility: Female

Participant eligibility is based on self-representation of gender identity.

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jordan Collaborating Cardiology Group
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ayman J. Hammoudeh, MD, FACC, Interventional Cardiologist, Department of cardiology, Istishari Hospital, Amman, Jordan – Jordan Collaborating Cardiology Group
  • Overall Official(s)
    • Reham Nasseddin, MD, Study Director, Jordan Collaborating Cardiology Group
    • Laith N Habahbeh, MD, Study Director, Jordan Collaborating Cardiology Group
  • Overall Contact(s)
    • Ayman J Hammoudeh, MD, FACC, 0096265001000, a.hammoudeh@istisharihospital.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.